Immuno-Oncology | Specialty

Published Ipilimumab/Nivolumab Data Highlight Activity in Metastatic RCC

July 12th 2017

Patients with metastatic renal cell carcinoma had an objective response rate of 40% and a 2-year overall survival rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016.

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

July 11th 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Findings Highlight Efficacy of Sipuleucel-T in African-American Men With Prostate Cancer

July 11th 2017

Oliver Sartor, MD, discusses the analysis of African-American men receiving sipuleucel-T for castrate-resistant prostate cancer compared with Caucasians, and the implications of this research.

Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer

July 11th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

July 7th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

Future Directions in Treating HNSCC

July 7th 2017

Emerging Agents to Treat HNSCC

July 7th 2017

Predictive Biomarkers in HNSCC

July 7th 2017

Patient Selection in Treating HNSCC

July 7th 2017

Nivolumab in HNSCC

July 7th 2017

Pembrolizumab in HNSCC

July 7th 2017

Checkpoint Inhibitors for Recurrent HNSCC

July 7th 2017

Checkpoint Inhibitors in HNSCC

July 7th 2017

Dr. Daud on the Combinations of Immunotherapy for Melanoma

July 6th 2017

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

Dr. Garon on Future of Immunotherapy in NSCLC

July 6th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the future of immunotherapy in the paradigm of non–small cell lung cancer (NSCLC).

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6th 2017

The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.

Expert Discusses Dramatic Impact of Immunotherapy on NSCLC Paradigm

July 6th 2017

Melissa Johnson, MD, discusses the impact of immunotherapy for patients with non-small cell lung cancer—those with both high and low levels of PD-L1 expression—and how the treatment and the role of PD-L1 will continue to progress in the coming years.

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

July 6th 2017

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma

July 5th 2017

Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.